Cooperative Agreement U01FD007954
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1M
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Great Britain, United Kingdom
Similar Awards
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $300,000.00 in funding to the University of Connecticut (UConn) to conduct research focused on developing physiologically-based pharmacokinetic (PBPK) model-based mechanistic in vitro-in vivo correlations (IVIVC) for long-acting injectable (LAI) drug suspensions. The key objectives of this 3-year project are to: 1) investigate the relationships between the...
This $1.5 million cooperative agreement from the Department of Health and Human Services' Food and Drug Administration (FDA) Research program (CFDA 93.103) supports the development and validation of a best practices framework for physiologically-based pharmacokinetic (PBPK) analysis to support model-informed biowaivers of fed bioequivalence studies for Biopharmaceutics Classification System Class II drugs. The University of Florida is the primary awardee. Under the award, the University of...
This Project Grant award of $1,207,500.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program supports research to advance the understanding of drug absorption processes. The research aims to systematically evaluate the particle drifting effect and de-supersaturation kinetics, both of which are key factors influencing oral drug bioavailability. The project will develop mass transport models, in vitro...
The University of Texas at Austin was awarded a $598,728 Cooperative Agreement from the Food and Drug Administration (FDA) Research program (CFDA 93.103) to develop physiologically-based pharmacokinetic (PBPK) model-based in vitro-in vivo correlations (IVIVC) for long-acting poly(lactic-co-glycolic acid) (PLGA) implants. The project aims to (1) develop a bio-predictive in-vitro release testing method and determine how critical formulation and physicochemical properties impact the in-vitro...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
The U.S. Food and Drug Administration (FDA) awarded a $249,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Simulations Plus Inc. for the project "From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions." The project aims to enhance understanding of how food and gastric pH affect the release of drugs from amorphous solid dispersions (ASDs) and how formulation and manufacturing variability...
This $150,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) will support the development of a personalized therapeutic drug monitoring (PTDM) system. The objective is to create a smart, home-use system that can provide frequent, noninvasive measurements of drug levels in a patient's saliva and deliver real-time data on circulating...
This Project Grant award of $170,490 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to develop and validate computable phenotypes for pediatric atopic dermatitis and compare the effectiveness and safety of dupilumab versus methotrexate for treating this condition. The funding will enable The Johns Hopkins University to utilize electronic health...
This $249,999.00 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) aims to mechanistically and systematically understand the effect of formulation composition, design, excipients, manufacturing methods, and process parameters on alcohol-induced dose dumping in extended-release drug products. The objectives are to investigate drug-related, formulation-related, and...